Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-1β-pretreated mesenchymal stem cells
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
IL-1β-pretreated mesenchymal stem cells (βMSCs) are a modified cell therapy product where human umbilical cord-derived mesenchymal stem cells are stimulated with the pro-inflammatory cytokine interleukin-1β (IL-1β) prior to administration. This pretreatment enhances the therapeutic efficacy of the MSCs by upregulating the expression of miR-146a, an anti-inflammatory microRNA, which is then selectively packaged into exosomes. These exosomes are transferred to macrophages, promoting their polarization toward an anti-inflammatory M2 phenotype. In preclinical studies, βMSCs have demonstrated superior ability to ameliorate symptoms and increase survival in murine models of sepsis compared to naïve MSCs, suggesting a potential modality for treating severe inflammatory disorders.
- Other names
- βMSCsIL-1β-pretreated MSCsinterleukin-1β-pretreated mesenchymal stem cellsIL-1β-primed mesenchymal stem cellsIL-1β-pretreated human umbilical cord-derived mesenchymal stem cells
Beyond the preview
Go deeper on IL-1β-pretreated mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-1β-pretreated mesenchymal stem cells.